# Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT01769196** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 544 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Simtuzumab
- **DRUG:** Simtuzumab placebo

## Key facts

- **NCT ID:** NCT01769196
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01-31
- **Primary completion:** 2016-02-23
- **Final completion:** 2016-02-23
- **Target enrollment:** 544 (ACTUAL)
- **Why stopped:** The Study was terminated due to lack of efficacy.
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01769196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01769196, "Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01769196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*